Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
NCT02044601
Withdrawn
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of onartuzumab that can be given with erlotinib and standard chemoradiation (paclitaxel and carboplatin) to patients with NSCLC. The goal of Phase II is to learn if onartuzumab plus erlotinib and chemoradiation can help to control NSCLC. The safety of this drug will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2014
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
NCT01235897
Completed
The purpose of this study is to test the safety and safest highest dose of an investigational drug called MK-2206 when given in combination with paclitaxel and trastuzumab in patients with Human Epidermal growth factor Receptor 2 (HER2)-overexpressing solid tumor malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2014
Locations: University of California, San Francisco, San Francisco, California
Conditions: Advanced Solid Tumors, Tumors, Cancer
Register for Updates
Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer
NCT00724386
Completed
The goal of this study is to determine the feasibility based on toxicity and response rate of giving paclitaxel weekly with concomitant every-other week radiotherapy to limit skin toxicity. This study will also seek to determine the maximally tolerated dose of Navelbine added to this combination when followed by Filgrastim and the dose-limiting toxicities of this regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2014
Locations: University of Chicago, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates
STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
NCT00084214
Completed
This study is designed to assess the efficacy of a weekly treatment regimen of STA-4783 and paclitaxel in comparison to paclitaxel alone on tumor response in metastatic melanoma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2014
Locations: Genesis Cancer Center, Hot Springs, Arkansas +27 locations
Conditions: Melanoma
Register for Updates
STA-4783 and Paclitaxel for Treatment of Solid Tumors
NCT00088114
Completed
The purpose of this study is to determine the safety, toxicity and maximum tolerated dose of single doses of STA-4783/paclitaxel in combination when administered intravenously to patients with refractory cancer. To determine the pharmacokinetics of STA-4783 and paclitaxel when co-administered. To assess the anti-tumor activity of STA-4783 and paclitaxel when co-administered.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2014
Locations: Beth Israel-Deaconess Medical Center, Boston, Massachusetts +1 locations
Conditions: Neoplasms
Register for Updates
Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
NCT00369551
Terminated
This phase I trial studies how well giving bevacizumab together with paclitaxel, carboplatin, and radiation therapy to the chest works in treating patients with locally advanced non-small cell lung cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2014
Locations: University of Chicago, Chicago, Illinois
Conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Stage II Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Register for Updates
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
NCT00666991
Completed
The purpose of this study is to evaluate the safety, pharmacokinetics and preliminary efficacy of an intraperitoneally administered suspension of nanoparticulate paclitaxel in patients with refractory malignancies principally confined to the peritoneal cavity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2014
Locations: University of Kansas Medical Center, Kansas City, Kansas +2 locations
Conditions: Peritoneal Neoplasms
Register for Updates
Phase I Trial of Paclitaxel With Perifosine
NCT00399126
Completed
This is a study of the drug perifosine given in combination with paclitaxel. Perifosine is an oral anti-cancer agent that has been used in more than 140 people. Paclitaxel is a standard chemotherapy agent used in many types of cancer. This study is designed to determine the highest dose of perifosine that can be administered to people every day while they are receiving paclitaxel in one of two regimens, without severe or prolonged nausea, vomiting and diarrhea. This study starts with patients ta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/12/2014
Locations: AOI Pharmaceuticals Investigative Site, Johnson City, Tennessee
Conditions: Neoplasms
Register for Updates
Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
NCT01014351
Completed
Based on data demonstrating synergy between paclitaxel and mammalian target of rapamycin (mTOR) inhibition, the investigators propose that the addition of everolimus to paclitaxel with carboplatin should lead to improvements in efficacy as measured by progression-free survival and response rate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2014
Locations: Florida Cancer Specialists, Fort Myers, Florida +11 locations
Conditions: Metastatic Melanoma
Register for Updates
A Pilot Study of PPX in Women With Metastatic Colorectal Cancer
NCT00598247
Completed
This study uses the drug PPX (also called Xyotax and CT-2103) in women with advanced colorectal cancer. PPX is an experimental drug that has not been approved by the Food and Drug Administration (FDA). PPX has been shown in the laboratory and in studies in humans to cause some cancer cells to die and some tumors to shrink. Women in some studies with PPX have been shown to live longer than the men that receive the drug. Some studies in humans suggest that estrogen (a hormone found in women) may p... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/05/2014
Locations: University of Southern California (U.S.C.)/ Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Advanced Colorectal Cancer
Register for Updates
Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
NCT00522834
Terminated
"Elesclomol (STA-4783), N-malonyl-bis (N'-methyl-N'-thiobenzoylhydrazide) is a new chemical entity with a novel structure. STA-4783 induces an oxidative stress response in cells. This response is characterized by increased production of gene families that protect against different cellular stresses, including excessive heat, the presence of reactive oxygen species such as oxygen radicals, or the presence of heavy metals. Subjects will participate in up to 2 weeks of screening during which time... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2014
Locations: Arizona Cancer Center, Tucson, Arizona +100 locations
Conditions: Melanoma
Register for Updates
Treatment With Pazopanib for Neoadjuvant Breast Cancer
NCT00849472
Completed
The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a pathological complete response in females with breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/30/2014
Locations: GSK Investigational Site, Decatur, Alabama +142 locations
Conditions: Neoplasms, Breast
Register for Updates